206 related articles for article (PubMed ID: 17140441)
1. Improving the use of research evidence in guideline development: 4. Managing conflicts of interests.
Boyd EA; Bero LA
Health Res Policy Syst; 2006 Dec; 4():16. PubMed ID: 17140441
[TBL] [Abstract][Full Text] [Related]
2. Guideline funding and conflicts of interest: article 4 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
Boyd EA; Akl EA; Baumann M; Curtis JR; Field MJ; Jaeschke R; Osborne M; Schünemann HJ;
Proc Am Thorac Soc; 2012 Dec; 9(5):234-42. PubMed ID: 23256165
[TBL] [Abstract][Full Text] [Related]
3. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings.
Lurie P; Almeida CM; Stine N; Stine AR; Wolfe SM
JAMA; 2006 Apr; 295(16):1921-8. PubMed ID: 16639051
[TBL] [Abstract][Full Text] [Related]
4. Improving the use of research evidence in guideline development: 1. Guidelines for guidelines.
Schünemann HJ; Fretheim A; Oxman AD;
Health Res Policy Syst; 2006 Nov; 4():13. PubMed ID: 17118181
[TBL] [Abstract][Full Text] [Related]
5. Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: associations with recommendations.
Nejstgaard CH; Bero L; Hróbjartsson A; Jørgensen AW; Jørgensen KJ; Le M; Lundh A
Cochrane Database Syst Rev; 2020 Dec; 12(12):MR000040. PubMed ID: 33289919
[TBL] [Abstract][Full Text] [Related]
6. Improving the use of research evidence in guideline development: 2. Priority setting.
Oxman AD; Schünemann HJ; Fretheim A
Health Res Policy Syst; 2006 Nov; 4():14. PubMed ID: 17134481
[TBL] [Abstract][Full Text] [Related]
7. Improving the use of research evidence in guideline development: 3. Group composition and consultation process.
Fretheim A; Schünemann HJ; Oxman AD
Health Res Policy Syst; 2006 Nov; 4():15. PubMed ID: 17134482
[TBL] [Abstract][Full Text] [Related]
8. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement.
Schünemann HJ; Fretheim A; Oxman AD
Health Res Policy Syst; 2006 Dec; 4():22. PubMed ID: 17147811
[TBL] [Abstract][Full Text] [Related]
9. Improving the use of research evidence in guideline development: 8. Synthesis and presentation of evidence.
Oxman AD; Schünemann HJ; Fretheim A
Health Res Policy Syst; 2006 Dec; 4():20. PubMed ID: 17147809
[TBL] [Abstract][Full Text] [Related]
10. Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study.
Elder K; Turner KA; Cosgrove L; Lexchin J; Shnier A; Moore A; Straus S; Thombs BD
CMAJ; 2020 Jun; 192(23):E617-E625. PubMed ID: 32538799
[TBL] [Abstract][Full Text] [Related]
11. Improving the use of research evidence in guideline development: 14. Reporting guidelines.
Oxman AD; Schünemann HJ; Fretheim A
Health Res Policy Syst; 2006 Dec; 4():26. PubMed ID: 17156458
[TBL] [Abstract][Full Text] [Related]
12. Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.
Grundy Q; Parker L; Wong A; Fusire T; Dimancesco D; Tisocki K; Walkowiak H; Vian T; Kohler J
Global Health; 2022 Mar; 18(1):33. PubMed ID: 35303902
[TBL] [Abstract][Full Text] [Related]
13. Financial Relationships between Organizations That Produce Clinical Practice Guidelines and the Biomedical Industry: A Cross-Sectional Study.
Campsall P; Colizza K; Straus S; Stelfox HT
PLoS Med; 2016 May; 13(5):e1002029. PubMed ID: 27244653
[TBL] [Abstract][Full Text] [Related]
14. Improving the use of research evidence in guideline development: 7. Deciding what evidence to include.
Oxman AD; Schünemann HJ; Fretheim A
Health Res Policy Syst; 2006 Dec; 4():19. PubMed ID: 17140445
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Improving the use of research evidence in guideline development: 16. Evaluation.
Oxman AD; Schünemann HJ; Fretheim A
Health Res Policy Syst; 2006 Dec; 4():28. PubMed ID: 17156460
[TBL] [Abstract][Full Text] [Related]
17. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
18. Improving the use of research evidence in guideline development: 12. Incorporating considerations of equity.
Oxman AD; Schünemann HJ; Fretheim A
Health Res Policy Syst; 2006 Dec; 4():24. PubMed ID: 17147814
[TBL] [Abstract][Full Text] [Related]
19. A Politics of Objectivity: Biomedicine's Attempts to Grapple with "non-financial" Conflicts of Interest.
Grundy Q
Sci Eng Ethics; 2021 Jun; 27(3):37. PubMed ID: 34097141
[TBL] [Abstract][Full Text] [Related]
20. Policies on faculty conflicts of interest at US universities.
Cho MK; Shohara R; Schissel A; Rennie D
JAMA; 2000 Nov; 284(17):2203-8. PubMed ID: 11056591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
